Singapore markets open in 2 hours 59 minutes
Straits Times Index
3,095.59 -6.62 (-0.21%) S&P 500
3,825.33 +39.95 (+1.06%) Dow
31,097.26 +321.86 (+1.05%) Nasdaq
11,127.84 +99.14 (+0.90%) BTC-USD
19,294.49 -53.35 (-0.28%) CMC Crypto 200
420.84 +0.70 (+0.17%)
ORPHAZYME A/S DK 1 (1TB.BE)
Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
At close: 09:34PM CEST
| Previous close | 0.2570 |
| Open | 0.2530 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.2530 - 0.2844 |
| 52-week range | 0.1727 - 6.2650 |
| Volume | |
| Avg. volume | 23 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
- Zacks
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
- Zacks
All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
© 2022 Yahoo. All rights reserved.
